Inclusion Criteria:

- Written informed consent.

- The diagnosis HCC is confirmed by typical appearance on imaging or cytohistological
evaluation (liver biopsy).

- Accurate staging:

MRI of the liver CT-scan of the abdomen and thorax bone scintigraphy, only in case of
clinical symptoms suggestive of skeletal metastases.

Exclusion Criteria:

- Hypersensitivity to doxorubicin

- Pregnancy or breastfeeding

- Age under 18 years

- Child-Pugh score >B7

- ECOG performance status (PST) > 1

- Bilirubin > 2.6 mg/dl

- AST/ALT >5x upper limit of normal (ULN)

- >50% of liver involvement

- Main portal vein (right, left or common trunk) thrombosis

- Extra-hepatic disease

- Previous treatment of study target lesions

- 99mTc-labelled macroaggregated albumin (99mTc-MAA) scintigraphy shows lack of MAA
uptake in tumor (photopenic lesion)

- Activity > 610 MBq and activity reduction would imply a liver target dose > 80 Gy

- patients who are declared incompetent or suffering from physic disorders that make a
comprehensive judgement impossible, such as psychosis.

- Unmanageable intolerance for contrast medium

- Life expectancy < 3 months or otherwise impossible follow-up

- Inadequate bone marrow, liver and/or renal function

- other contraindications to hepatic embolization procedures.